Log in to save to my catalogue

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant p...

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant p...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04388702v1

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Publication information

Publisher

Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundLutetium-177 ( 177Lu) prostate-specific membrane antigen ( 177Lu-PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Predictors of outcomes after 177Lu-PSMA to enhance its clinical implementation are yet to be identified. We aimed to develop nomograms to predict outcomes af...

Alternative Titles

Full title

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_04388702v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04388702v1

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(21)00274-6

How to access this item